Browse articles from EyeWorld.org related to gene therapy. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Phase 2 trial with experimental geographic atrophy treatment shows preservation of visual function ➤ AI-enabled screening system receives FDA clearance ➤ Enrollment complete for study evaluating investigational first-line therapy for DME ➤ Updates from two retinitis pigmentosa trials ➤ ASCRS news and events
➤ Researchers discover new class of drugs that could treat retinal dystrophies ➤ Enrollment complete in Phase 1/2a study using novel dry eye treatment approach ➤ NDA submitted to FDA for investigational inflammation and pain treatment ➤ Study: first-in-human gene therapy trial for achromatopsia ➤ ASCRS news and events
➤ FDA approves new monofocal IOL ➤ Topline Phase 3 results for fixed-dose combination presbyopia drop ➤ Gene therapy trial produces positive Phase 1/2 data for Leber congenital amaurosis ➤ New data shows investigational compound protects endothelium for cataract patients undergoing Fuchs treatment ➤ ASCRS news and events
➤ FDA approves twice-daily use of presbyopia drop ➤ Study: drug approved for high blood pressure shows promise for blinding childhood disease ➤ Breakthrough device designation granted to investigational dry AMD therapy ➤ Positive topline results for Phase 2 study of retinitis pigmentosa treatment ➤ FDA approves pediatric enrollment in trial for retinitis pigmentosa and Leber congenital amaurosis ➤ ASCRS news and events
➤ Positive preclinical results for non-viral gene therapy platform ➤ Real-world data confirms efficacy of investigational LHON therapy ➤ Largest genome wide study of photoreceptor cells to date ➤ CDC continues to investigate infectious outbreak associated with artificial tear use ➤ Updates from AAV-based gene therapy program for retinal conditions ➤ ASCRS news and events
➤ FDA approves first pharmacologic treatment of ROP for preterm infants ➤ FDA accepts NDA for dilation reversal drop ➤ Phase 2b results for anti-VEGF agent for wet AMD ➤ Interim results for Phase 1 study evaluating hydrogel implant for retinal diseases ➤ Data from ongoing Phase 1/2 clinical trial of gene therapy for Leber congenital amaurosis ➤ ASCRS news and events
➤ Bausch + Lomb acquires AcuFocus ➤ Study: novel drug delivery system sees less inflammation with preserved drops ➤ Meibomian gland atrophy common among cataract patients, study finds ➤ mRNA technology investigated for gene therapy to treat blindness ➤ Studies find new bionic vision system offers improved outcomes ➤ ASCRS news and events
➤ NDA submitted to FDA for drug that reverses mydriasis ➤ FDA cleared IND application for gene therapy to treat form of Leber congenital amaurosis ➤ FDA approves IND for research to move forward on RP gene therapy ➤ Phase 2 study to treat geographic atrophy begins ➤ Study: Weaning patients off of AMD treatments compared ➤ Possible geographic atrophy treatment explored ➤ ASCRS news and events
➤ NDA submitted to FDA for once-daily glaucoma drop ➤ Positive Phase 3 data for novel preservative-free latanoprost delivery method ➤ Phase 4 DME safety study reduces need for treatments ➤ New data from Phase 3 trial for investigational Acanthamoeba keratitis treatment ➤ New findings on visual potential for adults with Leber congenital amaurosis ➤ ASCRS news and events
➤ FDA approves new therapy for amblyopia ➤ First-in-human data from IOL/drug-delivery platform ➤ Largest crosslinking study to date for keratoconus ➤ Interim data for Phase 2 trial evaluating choroidal melanoma treatment ➤ Gene therapy update ➤ SLT trial seeking more clinical sites, deadline October 14 ➤ Acquisition news ➤ ASCRS news and events